This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Catheter Ablation Versus Thoracoscopic Ablation to Patients With Permanent Atrial Fibrillation

This study has been terminated.
(Patients with permanent AF are seldomly symptomatic enough to justify intervention. We decided to stop inclusion due to low recruitment rate.)
Information provided by:
Rigshospitalet, Denmark Identifier:
First received: February 23, 2006
Last updated: September 1, 2010
Last verified: July 2007

Patents with atrial fibrillation can be treated with the purpose of curing the arrhythmia.This may be achieved by catheter ablation and Maze surgery where the latter includes open heart surgery.

By catheter ablation the arrhythmia can be cured in about 70 % of patients who have episodes of atrial fibrillation. In patients with permanent atrial fibrillation the results are not as good.

We will compare a conventional ablation approach where lesions are created on the inside of the heart with a thoracoscopic approach where the lesions are created from the outside of the heart.

Condition Intervention
Atrial Fibrillation Procedure: Catheter ablation Procedure: Thoracoscopic epicardial ablation

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Study That Will Show the Effects of Catheter Ablation Compared to the Effects of Thoracoscopic Ablation to Patients With Permanent Atrial Fibrillation.

Resource links provided by NLM:

Further study details as provided by Rigshospitalet, Denmark:

Primary Outcome Measures:
  • Presence of sinus rhythm [ Time Frame: after 6 months from treatment ]

Secondary Outcome Measures:
  • complications [ Time Frame: during 12 months from treatment ]
  • cost-effectiveness [ Time Frame: during 12 months from treatment ]
  • structural changes (evaluated by echocardiography) [ Time Frame: during 12 months from treatment ]
  • p-BNP [ Time Frame: during 12 months from treatment ]
  • inflammatory markers [ Time Frame: during 12 months from treatment ]
  • atrial fibrillation burden evaluated by Holter monitoring [ Time Frame: at 6 months from treatment ]
  • exercise performance [ Time Frame: at 3 months from treatment ]
  • Quality of life [ Time Frame: at 3 months from treatment ]

Estimated Enrollment: 200
Study Start Date: November 2006
Estimated Study Completion Date: November 2010
Detailed Description:

Patients with permanent atrial fibrillation will be considered for randomisation Patients will be randomised to either conventional endocardial catheter ablation or epicardial thoracoscopic ablation.

Objectives of study:

Primary endpoint:presence of sinus rhythm after 6 months Secondary endpoints: complications, cost-effectiveness, structural changes (evaluated by echocardiography), p-BNP and inflammatory markers, atrial fibrillation burden evaluated by Holter monitoring


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Permanent atrial fibrillation documented on at least 2 ecg´s with more than 1 month between ecg´s. The diagnosis is verified on Holter.
  • All patients have symptoms or do not tolerate rate control treatment.

Exclusion Criteria:

  • Psychiatric disease or suspicion of incapability to give informed concent
  • Females with birth giving potential
  • Previous heart surgery
  • Previous ablation for atrial fibrillation
  • Life expectance less than 1 year
  • Congenital heart disease
  • Expected need for heart surgery
  • Heart failure (NYHA class IV)
  • Inability to be treated with anticoagulation
  • In case of previous deep venous thromboembolism og stroke the investigators will individually consider if the patient is suitable for inclusion.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00296166

Copenhagen, Denmark, 2100
Sponsors and Collaborators
Rigshospitalet, Denmark
Principal Investigator: Jesper H Svendsen, MD Rigshospitalet, Denmark
  More Information Identifier: NCT00296166     History of Changes
Other Study ID Numbers: KAT-SKOPI study
KF - 01-284215
Study First Received: February 23, 2006
Last Updated: September 1, 2010

Keywords provided by Rigshospitalet, Denmark:
Atrial fibrillation
Permanent Atrial fibrillation
catheter ablation

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes processed this record on August 18, 2017